Coraline Mlynarczyk

Coraline Mlynarczyk

Auto-generated profile, based on publicly available information

Coraline Mlynarczyk

Yale University 15 New Haven, CT

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Immunological Reviews
Verified
Journal Article
Open access
PDF file
CMCoraline Mlynarczyk
Coraline Mlynarczyk
LFLorena Fontán
Lorena Fontán
AMAri Melnick
Ari Melnick
Summary: One of the unusual features of germinal center (GC) B cells is that they manifest many hallmarks of cancer cells. Accordingly, most B‐cell neoplasms originate from the GC reaction, and characteristically display abundant point mutations, structural genomic lesions, and clonal diversity from the genetic and epigenetic standpoints. The dominant biological theme of GC‐derived lymphomas is mutation of genes involved in epigenetic regulation and immune receptor signaling, which come into play at critical transitional stages of the GC reaction. Hence, mechanistic studies of these mutations reveal fundamental insight into the biology of the normal and malignant GC B cell. The BCL6 transcription factor plays a central role in establishing the GC phenotype in B cells, and most lymphomas are dependent on BCL6 to maintain survival, proliferation, and perhaps immune evasion. Many lymphoma mutations have the commonality of enhancing the oncogenic functions of BCL6, or overcoming some of its tumor suppressive effects. Herein, we discuss how unique features of the GC reaction create vulnerabilities that select for particular lymphoma mutations. We examine the interplay between epigenetic programming, metabolism, signaling, and immune regulatory mechanisms in lymphoma, and discuss how these are leading to novel precision therapy strategies to treat lymphoma patients.

17 December 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JPJuhee Pae
Juhee Pae
JEJonatan Ersching
Jonatan Ersching
TCTiago B.R. Castro
Tiago B.R. Castro
MSMarta Schips
Marta Schips
LMLuka Mesin
Luka Mesin
GVGabriel D. Victora
Gabriel D. Victora
During affinity maturation, germinal center (GC) B cells alternate between proliferation and somatic hypermutation in the dark zone (DZ) and affinity-dependent selection in the light zone (LZ). This anatomical segregation imposes that the vigorous proliferation that allows clonal expansion of positively selected GC B cells takes place ostensibly in the absence of the signals that triggered selection in the LZ, as if by “inertia.” We find that such inertial cycles specifically require the cell cycle regulator cyclin D3. Cyclin D3 dose-dependently controls the extent to which B cells proliferate in the DZ and is essential for effective clonal expansion of GC B cells in response to strong T follicular helper (Tfh) cell help. Introduction into the Ccnd3 gene of a Burkitt lymphoma–associated gain-of-function mutation (T283A) leads to larger GCs with increased DZ proliferation and, in older mice, clonal B cell lymphoproliferation, suggesting that the DZ inertial cell cycle program can be coopted by B cells undergoing malignant transformation.

20 January 2023 in Science
Verified
Journal Article
Closed access
CMCoraline Mlynarczyk
Coraline Mlynarczyk
MTMatt Teater
Matt Teater
JPJuhee Pae
Juhee Pae
CCChristopher R. Chin
Christopher R. Chin
LWLing Wang
Ling Wang
AMAri Melnick
Ari Melnick
Multicellular life requires altruistic cooperation between cells. The adaptive immune system is a notable exception, wherein germinal center B cells compete vigorously for limiting positive selection signals. Studying primary human lymphomas and developing new mouse models, we found that mutations affecting BTG1 disrupt a critical immune gatekeeper mechanism that strictly limits B cell fitness during antibody affinity maturation. This mechanism converted germinal center B cells into supercompetitors that rapidly outstrip their normal counterparts. This effect was conferred by a small shift in MYC protein induction kinetics but resulted in aggressive invasive lymphomas, which in humans are linked to dire clinical outcomes. Our findings reveal a delicate evolutionary trade-off between natural selection of B cells to provide immunity and potentially dangerous features that recall the more competitive nature of unicellular organisms.

29 December 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
LSLaurianne Scourzic
Laurianne Scourzic
FIFranco Izzo
Franco Izzo
MTMatt Teater
Matt Teater
APAlexander P. Polyzos
Alexander P. Polyzos
LCLucretia Cucereavii
Lucretia Cucereavii
EAEffie Apostolou
Effie Apostolou

3 September 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ELEtienne Leveille
Etienne Leveille
SKShalin Kothari
Shalin Kothari
KCKadriye N. Cosgun
Kadriye N. Cosgun
CMCoraline Mlynarczyk
Coraline Mlynarczyk
MMMarkus Müschen
Markus Müschen
Summary: Polatuzumab vedotin, an antibody–drug conjugate targeting CD79B, is the first new drug approved for first-line therapy of diffuse large B-cell lymphoma in more than two decades, although factors determining treatment responses to polatuzumab vedotin remain unknown. Two new studies identified central mechanisms of lower sensitivity, namely reduced accessibility of the CD79B epitope through N-linked glycosylation of CD79B and lower CD79B surface expression levels due to the activity of the KLHL6 E3 ligase. See related article by Corcoran et al., p. 1653 (6) See related article by Meriranta et al. (7).

21 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
BPBenedikt Pelzer
Benedikt Pelzer
CMCem Meydan
Cem Meydan
ISIsaac M. Spiegel
Isaac M. Spiegel
IOANNIS KARAGIANNIDISIOANNIS KARAGIANNIDIS
IOANNIS KARAGIANNIDIS
MXMin Xia
Min Xia
AMAri M. Melnick
Ari M. Melnick
Diffuse large B-cell lymphomas (DLBCL) are genetically and phenotypically heterogeneous, making diagnosis and treatment challenging. Current models suggest DLBCL derive from follicular B cells engaged in adaptive immune responses. By studying co-occurring truncating mutations in SPEN and NOTCH2 in the BN2-DLBCL subtype, our data suggest a previously unrecognized extra-follicular trajectory. Using animal models and human specimens, we find this cooperative mutational axis supports expansion of putative clonal precursors with features of marginal zone, memory and a distinct, autoimmune B-cell-like state. This trajectory is associated with sex-biased outcomes: female patients and mice exhibit reduced survival compared to males in our cohorts. Further analysis links this disparity to enhanced X-chromosome-linked expression and functionality of toll-like receptor signaling. We show that IRAK inhibition represents a potential sex-specific therapeutic strategy in preclinical models. These findings support a distinct developmental origin for BN2-DLBCL and identify a high-risk female population with actionable targets for precision therapy.